TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05428449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT20029 Gel
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GT20029 Gel Placebo
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Study: NCT05032859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapinarof cream, 1%
Description: applied topically once daily
Study: NCT04547439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be given nightly for 8 weeks
Study: NCT06080477

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted ENHANCE Intervention
Description: Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.
Study: NCT04691648

Intervention type: DRUG
Intervention: Gilteritinib Exposure
Description: Oral
Study: NCT05581173

Intervention type: DEVICE
Intervention: Purastat SAP gel application
Description: Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
Study: NCT05893498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFRangio
Description: A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR or NHPR
Description: Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
Study: NCT05286814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
Study: NCT05032859

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: applied topically once daily
Study: NCT05851625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Description: Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plesterin
Description: The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
Study: NCT06409767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.
Description: The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
Study: NCT06252740

Intervention type: OTHER
Intervention: No intervention
Description: Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain

Intervention type: OTHER
Intervention: No intervention
Description: Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain
Study: NCT06060704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: 35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
Study: NCT05824767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
Study: NCT05782374

Intervention type: DRUG
Intervention: Ibrutinib
Description: ibrutinib alone or in combination with R-CHOP or R-CHOP like
Study: NCT05509738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses.
Study: NCT05286814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
Study: NCT04835532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone gereration
Description: guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone gereration
Description: guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone gereration
Description: guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation.
Study: NCT05173662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process
Description: Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
Study: NCT05270343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vit D3) 400Unit Cap
Description: Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
Study: NCT06505512

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT06411197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: Injection with hypertonic saline (7%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: Injection with hypertonic saline (7%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: Injection with hypertonic saline (7%)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline injection
Description: Injection with isotonic saline (0.9%)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline injection
Description: Injection with isotonic saline (0.9%)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline injection
Description: Injection with isotonic saline (0.9%)
Study: NCT04923191

Intervention type: OTHER
Group type: OTHER
Intervention: Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
Description: percutaneous coronary intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
Description: percutaneous coronary intervention
Study: NCT05089942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Insulin Patch ZJSRM2021
Description: health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: health subjects receive placebo patch
Study: NCT05286814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
Study: NCT06291545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）
Description: One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
Study: NCT05286814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intera 3000 Hepatic Artery Infusion Pump (HAIP)
Description: Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intera 3000 Hepatic Artery Infusion Pump (HAIP)
Description: Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
Study: NCT06291545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ScoreFlex NC Coronary Dilatation Catheter
Description: One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
Study: NCT06068647

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations
Description: Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level.
Study: NCT06357962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-permanent acupuncture
Description: These are sessions that last approximately one hour. The selection of points will be based on the energy diagnosis made during the first visit. In some cases, a point may be changed depending on progress. During the session, an interrogation will be conducted to assess symptoms and signs of the condition, and to evaluate if there have been any adverse reactions to the previous session. At the end of the visit, semi-permanent acupuncture will be applied to the selected points.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham of semi-permanent acupuncture
Description: A simulated semi-permanent acupuncture session will be conducted, consisting of specific placebo materials without needles and without stimulation for a few minutes. These points will not correspond to any acupuncture point and will be located on the hands, feet, and back. Stickers without pins will be applied, but never in critical points related to contraction stimulation or cervical ripening.
Study: NCT05231538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy
Description: NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
Study: NCT06161025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DXd
Description: R-DXd will be administered as an intravenously (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DXd
Description: R-DXd will be administered as an intravenously (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DXd
Description: R-DXd will be administered as an intravenously (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DXd
Description: R-DXd will be administered as an intravenously (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: PLD will be administered as an IV infusion
Study: NCT05669482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
Description: The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
Description: The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
Study: NCT05821855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XEN45 Glaucoma Treatment System
Description: Ab interno implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Surgical Intervention
Study: NCT05537740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3375968
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3375968
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3375968
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3375968
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04773353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta (FE 999049)
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa (GONAL-F)
Description: GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
Study: NCT05708833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous venous access
Description: Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral venous access
Description: Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
Study: NCT04954833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-200
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-200
Description: TEST Lens